CATALOGO DEI PRODOTTI DELLA RICERCA

BONIFACIO, Massimiliano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.209
EU - Europa 6.449
AS - Asia 5.656
SA - Sud America 931
AF - Africa 106
OC - Oceania 34
Continente sconosciuto - Info sul continente non disponibili 7
AN - Antartide 1
Totale 20.393
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.067
CN - Cina 2.078
SG - Singapore 2.002
RU - Federazione Russa 1.715
GB - Regno Unito 1.507
BR - Brasile 785
IT - Italia 656
HK - Hong Kong 629
DE - Germania 513
SE - Svezia 486
FR - Francia 444
IE - Irlanda 410
VN - Vietnam 365
FI - Finlandia 292
KR - Corea 139
UA - Ucraina 100
IN - India 99
CA - Canada 76
NL - Olanda 73
ID - Indonesia 63
AR - Argentina 61
PL - Polonia 54
JP - Giappone 52
MX - Messico 43
TR - Turchia 41
BE - Belgio 39
BD - Bangladesh 37
AT - Austria 32
ES - Italia 31
AU - Australia 29
IR - Iran 24
EC - Ecuador 23
TG - Togo 22
IQ - Iraq 20
ZA - Sudafrica 20
CO - Colombia 15
CL - Cile 14
MA - Marocco 14
RO - Romania 14
VE - Venezuela 14
BJ - Benin 12
UZ - Uzbekistan 12
AZ - Azerbaigian 11
CZ - Repubblica Ceca 10
GR - Grecia 10
CH - Svizzera 9
LT - Lituania 9
NP - Nepal 9
KZ - Kazakistan 8
DK - Danimarca 7
DZ - Algeria 7
NO - Norvegia 7
PE - Perù 7
PY - Paraguay 7
TN - Tunisia 7
AE - Emirati Arabi Uniti 6
CG - Congo 6
PK - Pakistan 6
CR - Costa Rica 5
KG - Kirghizistan 5
TW - Taiwan 5
EU - Europa 4
JM - Giamaica 4
JO - Giordania 4
LV - Lettonia 4
NZ - Nuova Zelanda 4
PT - Portogallo 4
AL - Albania 3
AM - Armenia 3
EG - Egitto 3
HU - Ungheria 3
IL - Israele 3
LA - Repubblica Popolare Democratica del Laos 3
LK - Sri Lanka 3
MY - Malesia 3
PA - Panama 3
PH - Filippine 3
QA - Qatar 3
SA - Arabia Saudita 3
TH - Thailandia 3
UY - Uruguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BG - Bulgaria 2
BH - Bahrain 2
BO - Bolivia 2
BY - Bielorussia 2
DM - Dominica 2
ET - Etiopia 2
GE - Georgia 2
HN - Honduras 2
KH - Cambogia 2
LY - Libia 2
MK - Macedonia 2
NG - Nigeria 2
NI - Nicaragua 2
RS - Serbia 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SY - Repubblica araba siriana 2
Totale 20.367
Salva come PNG Salva come JPEG
Città #
Southend 1.303
Chandler 968
Dallas 928
Singapore 798
Hong Kong 624
Woodbridge 505
Ashburn 496
Beijing 492
Moscow 487
Dublin 408
Ann Arbor 329
Jacksonville 267
Houston 262
Wilmington 194
Verona 188
New York 173
Lawrence 172
Princeton 172
Los Angeles 147
The Dalles 135
Jinan 133
Nanjing 122
Shenyang 122
Ho Chi Minh City 112
Munich 97
Redmond 88
Buffalo 80
Redondo Beach 78
Sindelfingen 78
Columbus 77
Hebei 76
Hanoi 73
Helsinki 73
São Paulo 66
Tianjin 64
Zhengzhou 54
Santa Clara 51
Changsha 47
Tokyo 47
Falls Church 46
Nanchang 46
Taizhou 45
Fuzhou 44
Ningbo 44
Warsaw 44
Milan 43
Redwood City 43
Bologna 42
Jakarta 42
Dong Ket 40
Brussels 39
Guangzhou 38
Chicago 37
Haikou 37
Hangzhou 37
Turku 37
Nuremberg 36
Seoul 36
Seattle 35
Norwalk 30
San Francisco 30
London 28
Kent 27
Rio de Janeiro 27
Chennai 26
Jiaxing 26
Montreal 26
Taiyuan 25
Atlanta 24
Belo Horizonte 24
Denver 24
Rome 24
Council Bluffs 22
Falkenstein 22
Lomé 22
Groningen 21
Poplar 21
Stockholm 19
Boston 18
Frankfurt am Main 18
Amsterdam 17
Boardman 17
Mexico City 17
Dearborn 16
Johannesburg 16
Orem 16
Provo 16
Düsseldorf 15
Lanzhou 15
Shanghai 15
Toronto 15
Vienna 15
Brasília 14
Lappeenranta 13
Phoenix 13
San Giovanni Lupatoto 13
Chengdu 12
Cotonou 12
Lancaster 12
Perth 12
Totale 12.192
Salva come PNG Salva come JPEG
Nome #
Epidemiology of mastocytosis in adults based on a multidisciplinary diagnostic approach. 277
CAL2 Monoclonal Antibody Is a Rapid and Sensitive Assay for the Detection of Calreticulin Mutations in Essential Thrombocythemia and May Provide Prognostic Informations 202
A study of the crosstalk between CD30 and CXCR4 201
Notch singalling inhibition as a multi-target therapy to overcome bone marrow microenvironment-mediated drug resistance in AML 201
Role of GSK-3 signalling in non-promyelocitic acute myeloid leukemia (AML) cell response to chemotherapy 197
CD66b-CD64dimCD115- cells in the human bone marrow represent neutrophil-committed progenitors 194
Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia 188
Role of Wnt/β-Catenin Signalling in Acute Myeloid Leukemia (AML) Cell Response to Chemotherapy 182
Inhibition of GSK-3 Signalling Enhances Sensitivity of Non-Promyelocitic Acute Myeloid Leukemia (AML) Cell to Chemotherapy 179
Clonal mast cell disorders limited to bone marrow: not a negligible disease. 179
BCR-ABL fusion transcript b2a2 is associated with a higher risk of non-optimal early response in CP-CML patients treated with standard dose imatinib: a study from Gruppo Triveneto LMC. 178
A preliminary experience with the HyperCHiDAM Verona intensive chemotherapy regimen in heavily pretreated refractory Hodgkin's lymphoma 176
Absence of TCL1A expression is a useful diagnostic feature in splenic marginal zone lymphoma. 173
CXCL12 and [N33A]CXCL12 in 5637 and HeLa Cells: Regulating HER1 Phosphorylation via Calmodulin/Calcineurin 171
Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis 169
Value of flow cytometry in the diagnosis of indolent systemic mastocytosis. 165
Longitudinal Evaluation of Bone Mineral Density and Bone Metabolism Markers in Patients with Indolent Systemic Mastocytosis Without Osteoporosis 163
ALK-positive anaplastic large cell lymphoma with PAX-5 expression: report of a case 162
Autoimmune complications are frequent in splenic and nodal marginal zone lymphomas 162
Predictors for response to ruxolitinib in real-life: an observational independent study on 266 patients with myelofibrosis 162
Predictive factors of stable deep molecular response in chronic myeloid leukemia patients treated with imatinib standard dose: a study from the Gruppo Triveneto LMC. 161
Inhibition of Notch signalling overcomes bone marrow stromal-mediated anti-apoptotic and chemoresistance effects in AML. 160
Somatic D816V KIT mutation in a case of adult-onset familial mastocytosis. 158
Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected 158
Rational of targeting WNT/beta-catenin signaling in acute myeloid leukemia (AML) 157
A simple score predicts clonal mast cell disorders in patients with systemic reactions to Hymenoptera venom without skin lesions 155
Predictors of stable deep molecular response in chronic phase chronic myeloid leukemia patients treated with dasatinib or nilotinib after imatinib failure 155
Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis 154
Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories 152
CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia and may provide prognostic informations 152
The Sesquiterpene Oil {alpha}-Bisabolol Induces Apoptosis of B-Chronic Lymphocytic Leukemia Primary Cells 151
A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis 151
α-bisabolol is an effective proapoptotic agent against BCR-ABL+ cells in synergism with Imatinib and Nilotinib 150
BLAST: A Confirmatory, Single-Arm, Phase 2 Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL) 150
Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels 147
Plasmacytoid dendritic cell leukemia: a rapidly evolving disease presenting with skin lesions sensitive to radiotherapy plus hyperthermia. 144
CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients 144
The impact of sensitive KIT D816V detection on recognition of Indolent Systemic Mastocytosis 143
Inhibition of Notch signaling enhances chemosensitivity in B cell precursor acute lymphoblastic leukemia 143
Regulative Loop between β-catenin and Protein Tyrosine Receptor Type γ in Chronic Myeloid Leukemia 140
Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response 139
Back to life – Living, treating, managing myelofibrosis: the burden of illness for patients and their families 138
A Multidisciplinary Diagnostic Approach Reveals a Higher Prevalence of Indolent Systemic Mastocytosis: 15-Years’ Experience of the GISM Network 137
Small Molecule Inhibitors of Microenvironmental Wnt/β-Catenin Signaling Enhance the Chemosensitivity of Acute Myeloid Leukemia 136
Pro-apoptotic activity of α-bisabolol in preclinical models of primary human acute leukemia cells 134
Improved detection of the C-KIT D816V mutation using allele-specific arms real time PCR assay allows a finer recognition of patients with indolent systemic mastocytosis. 134
Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis 134
The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population 133
The impact of a 7-day prednisone (PDN) pretreatment in adult (less than 60y) acute lymphoblastic leukemia (ALL) therapy: results of LAL2000 vs LAL0496. 132
Molecular “warning” CML patients: a retrospective study of Gruppo Triveneto LMC. 132
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy 131
Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia 130
Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis 129
Unexpected subacute leucoencephalopathy following intrathecal methotrexate and cytarabine administration in a patient homozygous for MTHFR 677C→T polymorphism. 129
Comparison of dasatinib and nilotinib as second-line therapy after imatinib failure in chronic phase chronic myeloid leukemia patients. 129
TP53 mutations in adult acute lymphoblastic leukemia (ALL) are relatively frequent in molecularly negative case of both B- and T-lineage and correlate with poor response to induction therapy 126
Real-life comparison of dasatinib and nilotinib as second-line therapy after imatinib failure for chronic phase CML 126
Multiple large osteolytic lesions in a patient with systemic mastocytosis: a challenging diagnosis 126
Bone Disease in Mastocytosis 126
Systemic mastocytosis: a muldisciplinary approach (Review) [Lamastocitosi sistemica: Un approccio multidiscliplinare] 125
Short-term, intensive chemotherapy regimen is equally effective in Burkitt lymphoma (BL) and in the novel WHO 2008 entity “B-cell lymphoma intermediate between DLBCL and BL". 125
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 125
Sesquiterpene α-bisabolol, which binds to Bid in lipid rafts, induces apoptosis in BCR/ABL+ cell lines through membrane depolarization. 124
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 124
Mitochondrial-Mediated Apoptosis by the Sesquiterpene Oil {alpha}-Bisabolol and Its Synergism with Imatinib and Nilotinib In BCR-ABL+ Cells. 123
Hyperchidam Verona897 Regimen Is Effective in Treatment of Advanced Peripheral T Cell Lymphoma (PTCL): The GITIL Experience in 33 Cases 122
Uncovering two neutrophil-committed progenitors that immediately precede promyelocytes during human neutropoiesis 119
Characterization of a new B-ALL cell line with constitutional defect of the Notch signaling pathway 118
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 117
High levels of tumor load reduction after intensive chemotherapy favorably affect the prognosis of BCR/ABL+ ALL adult patients receiving Imatinib Mesylate alone as a post-consolidation treatment according to the Italian GIMEMA LAL 0201/A protocol 116
Ultra-deep sequencing (UDS) allows more sensitive detection of the D816V and other KIT gene mutations in systemic mastocytosis 116
Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis 115
Regulative loop between beta-catenin and protein tyrosine phosphatase receptor type gamma (PTPRG) in chronic myeloid leukemia 115
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients 114
Serum tryptase levels differently change over time in indolent systemic mastocytosis with or without skin lesions. 114
High incidence of autoimmune complications in 82 patients with non-MALT marginal zone lymphomas. 113
BCR-ABL mutations in chronic myeloid leukemia (CML) patients (pts) with failure and warning to first- and second-lline tyrosine kinase inhibitor (TKI) therapy: what is the advantage of Next-Generation Sequencing (NGS) over conventional sequencing? 113
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 113
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients 113
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 112
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 112
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 112
Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements 111
A critical comparison of Sokal, Euro, and Eutos risk scores in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. 110
EUTOS Score Identifies Cases with Poor Outcome in Patients with Early Chronic Phase Chronic Myeloid Leukemia, Though Not Predictive for Optimal Response to Imatinib 109
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 109
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study 109
Skeletal implications of isolated bone marrow mastocytosis (reply): Indolent systemic mastocytosis without skin involvement vs. isolated bone marrow mastocytosis (reply) 108
In Chronic Myeloid Leukemia Patients on 2nd-Line Tyrosine Kinase Inhibitor Therapy, Deep Sequencing at the Time of Warning May Allow Sensitive Detection of Emerging BCR-ABL1 Mutants 108
PBX/E2A transcript positive B-lymphoblastic leukemia (B-ALL) presenting with bilateral renal and myocardial involvement: a case report. 108
A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements 107
Modified HyperCVAD and rituximab for the treatment of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. 107
Blastic plasmacytoid dendritic cell leukemia: preliminary results of a retrospective italian multicentric study. 106
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study 105
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 105
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged $greater$65~years resistant/intolerant to previous tyrosine-kinase inhibitors 103
The Plant-Derived Agent {alpha}-Bisabolol Induces Apoptosis of Leukemic Blasts Ex Vivo. 102
Combination of EUTOS score and 3-months BCR-ABL transcript level identifies a distinct subgroup of ECP-CML patients with high risk of non optimal response and imatinib discontinuation. 102
Genome-Wide Promoter Methylation Profiling Of Splenic Marginal Zone Lymphoma (SMZL) Identifies Two Subgroups Of Patients With Distinct Genetic and Biologic Features and Different Outcomes 101
Long-term outcomes after blinatumomab treatment: follow-up of a phase 2 study in patients (pts) with minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukemia (ALL). 100
Totale 13.817
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.385
article - articoli 52.578
book - libri 0
conference - conferenze 25.410
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 397
Totale 156.770
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021696 0 0 0 0 218 108 22 22 50 20 162 94
2021/20221.381 106 374 36 141 109 56 24 73 72 40 78 272
2022/20232.692 190 264 263 470 208 704 33 152 297 24 46 41
2023/20241.596 73 128 90 158 175 197 63 109 27 86 379 111
2024/20254.293 188 241 214 703 183 141 210 238 629 318 425 803
2025/20265.492 881 747 903 2.060 901 0 0 0 0 0 0 0
Totale 20.691